1. In Vivo
  2. >>Archive

Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse

Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.

An ounce of prevention is worth….$7 billion, which is what Siemens AG , the number two player in diagnostic imaging, has offered to become the number three player in in vitro diagnostics. Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products Corp., to bring an immunodiagnostics business in-house, [See Deal] Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. [See Deal] Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche , and by its calculations, now plays a close third to Abbott Laboratories Inc. in the overall in vitro diagnostics (IVD) market, excluding the diabetes self testing segment, in which Siemens doesn't operate.

Not only do the IVD acquisitions represent a new source of recurring revenues from diagnostic test and reagents to a company traditionally operating in capital equipment segments, the in vitro...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.